title: V559A and N822I double KIT mutant melanoma with predictable response to imatinib?
authors.forename: Kevin
authors.initials: K
authors.lastname: McDonnell
authors.forename: Bryan
authors.initials: B
authors.lastname: Betz
authors.forename: Douglas
authors.initials: D
authors.lastname: Fullen
authors.forename: Christopher D
authors.initials: CD
authors.lastname: Lao
mesh_terms: D000369:Aged, 80 and over; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D008545:Melanoma / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D009154:Mutation; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000037:antagonists & inhibitors / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit